The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

The St. Peter’s Hospital ALS Regional Center gives specialized services and resources to people with Amyotrophic Lateral ...

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...

Positive results of preclinical studies confirm the potential of Neurizon’s lead drug candidate NUZ-001 to be a ...

I pray that she carries the love that she felt tonight every day that she has," said friend Rita Monteiro, who organized the ...

It’s also worth mentioning that VYGR anticipates an IND submission by 2025 for its SOD1 gene therapy indicated for ...

Morgan Stanley's latest report pegs the BCI market at $400 billion — signaling to investors that this revolutionary ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

People come and go throughout our lives, but it’s to the ones who leave their mark and create solid foundations that we may ...